Drug Trial Radar · NCT06819826
A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
Last checked: Nov 19, 2026Latest source record: Feb 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
Feb 14, 2025
Primary completion
Dec 31, 2026
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Biocity Biopharmaceutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of SC0062 capsule compared to placebo in patients with IgA nephropathy in the presence of proteinuria. The participants must have a high risk of disease progression, despite of stable use of the maximum tolerated labelled or optimized dose of RAASi and/or SGLT2i for at least 12 weeks prior to randomization.
Conditions
- IgA Nephropathy (IgAN)
Interventions
SC0062 strength 10mgDrug
Subjects will take 20 mg once daily for 108 weeks during the treatment period.
Placebo matched to SC0062Drug
Subjects will take 20 mg once daily for 108 weeks during the treatment period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in 24-hour urine protein-to-creatinine ratio (24h-UPCR) at 36 weeksTime frame: Baseline, 36 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial People's Hospital
Guangzhou, Yuexiu District, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.